menu
    • menu
    [{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Exacis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"ExaNK","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Exacis Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Exacis Biotherapeutics"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"iPSC-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Hypoimmune Pluripotent Stem Cell","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eterna Therapeutics \/ Lineage Cell Therapeutics"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Exacis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"iPSC-based Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Eterna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Eterna Therapeutics"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IPSC-derived Cell Ttransplant Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eterna Therapeutics \/ Lineage Cell Therapeutics"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Factor Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"iPSC-based Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Eterna Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eterna Therapeutics \/ Eterna Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Eterna Therapeutics

    Menu

    Eterna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-based Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Factor Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eterna and Factor Bioscience Partner for Cell Therapy in Oncology and Rare Diseases

                            Details : Under the terms of the agreement, Eterna has exclusive license to develop and market certain iPSC-based cell therapy products utilizing Factor’s cell reprogramming and gene-editing technologies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 17, 2024

                            Lead Product(s) : iPSC-based Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Factor Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPSC-derived Cell Ttransplant Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Lineage Cell Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Ne...

                            Details : The novel hypoimmune iPSC line is a targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 06, 2023

                            Lead Product(s) : IPSC-derived Cell Ttransplant Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Lineage Cell Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Exacis Biotherapeutics

                            Deal Size : $49.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

                            Details : The acquisition includes global immuno-oncology platform of Exacis and its entire pipeline of engineered cell therapy programs for hematologic and solid tumors. Eterna will produce an unlimited number of mRNA-engineered NK and T-cell therapies derived fr...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 02, 2023

                            Lead Product(s) : iPSC-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Exacis Biotherapeutics

                            Deal Size : $49.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : Lincoln Park Capital

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Millio...

                            Details : The proceeds will be used to support the development of next-generation mRNA-based therapeutic products and deploying its extensive portfolio of in-licensed mRNA cell engineering patents through strategic partnerships.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 11, 2023

                            Lead Product(s) : mRNA-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : Lincoln Park Capital

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hypoimmune Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Lineage Cell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimm...

                            Details : Under the agreement, Eterna will develop the novel induced hypoimmune pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into cell transplant therapies and for the treatment of certain CNS disorders and other neurology indica...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : Hypoimmune Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Lineage Cell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-based Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

                            Details : Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna’s gene-edited induced pluripotent stem (iPS) cell therapeutic candidates to stimulate enhanced immune responses, including their effects on various aspects of T-cell mediated immuni...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 01, 2022

                            Lead Product(s) : iPSC-based Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eterna Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ExaNK

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Exacis Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Exacis Biotherapeutics Grants Eterna Therapeutics An Option To License Up To Four Allogeneic Ipsc-Derived Nk A...

                            Details : The opportunity to partner with Exacis and add next-generation mRNA-based NK (ExaNK) and T cell therapies to oncology portfolio is an important step in advancing Eterna’s mission to realize the potential of cell engineering to provide patients with new...

                            Brand Name : ExaNK

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : ExaNK

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Exacis Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth